Optimizing Post-Prostatectomy Radiotherapy: A Multi-Disciplinary Perspective
This continuing medical education activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation biologists, radiation physicists, dosimetrists, oncologists working in related specialties, radiation therapists, radiation oncology nurses, radiation oncology administrators, diagnostic radiologists and all other health professionals involved in the field of radiation oncology.
After this session, attendees should be able to:
- Understand the quality of evidence that supports post-prostatectomy radiotherapy, hormonal therapy and chemotherapy.
- Become familiar with the role of genomic signatures to stratify patients for adjuvant therapies following prostatectomy.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.